Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782934 | 0.87 | ALDH1A1 (0.59) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL19578097 | 0.87 | LMNA (0.59) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL13154002 | 0.86 | GAA (0.60) | ALDH1A1TSHRHPGDLMNACYP3A4 | |
| SCHEMBL888796 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL10298821 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL19364727 | 0.85 | SMN1; SMN2 (0.56) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL8930271 | 0.84 | MC4R (0.51) | ALDH1A1LMNAGAA | |
| SCHEMBL19334117 | 0.82 | KCNA3 (0.43) | ALDH1A1TSHRLMNAGAA | |
| SCHEMBL18889507 | 0.81 | ALDH1A1 (0.62) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA | |
| SCHEMBL8917009 | 0.81 | ALDH1A1 (0.62) | ALDH1A1TSHRSMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TSHR 4635/4885SMN1; SMN2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.